Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Paz-Ares, L.; Spira, A.; Raben, D.; Planchard, D.; Cho, B.; ÖZGÜROĞLU, Mustafa; Daniel, D.; Villegas, A.; Vicente, D.; Hui, R.; Murakami, S.; Spigel, D.; Senan, S.; Langer, C.; Perez, B.; Boothman, A-M; Broadhurst, H.; Wadsworth, C.; Dennis, P.; Antonia, S.; Faivre-Finn, C.

doi:10.1016/j.annonc.2020.03.287

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Paz-Ares L., Spira A., Raben D., Planchard D., Cho B. C., ÖZGÜROĞLU M., ...More

ANNALS OF ONCOLOGY, vol.31, no.6, pp.798-806, 2020 (SCI-Expanded)

Publication Type: Article / Article
Volume: 31 Issue: 6
Publication Date: 2020
Doi Number: 10.1016/j.annonc.2020.03.287
Journal Name: ANNALS OF ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
Page Numbers: pp.798-806
Istanbul University Affiliated: No

Abstract

Background: In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression.